Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3226 | RESP301, a Nitric Oxide generating solution Wiki | 1.00 |
| drug3728 | Standard of Care Wiki | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In order to inform the public decision on the containment strategy and knowledge of the intensity of the epidemic during post-containment, estimates of the share of the population infected with the SARS-CoV-2 virus responsible for COVID-19 disease at the territorial level are needed as soon as possible. The aim of the study is to estimate the prevalence of positive anti-SARS-CoV-2 serologies by detection of IgT-total antibodies (IgM/IgA/IgG) in the general population of the Grand Nancy Metropolitan area. A study of seroprevalence and symptom collection, or absence of symptoms, on a cluster (household) sample of the Grand Nancy Metropolitan population randomly selected will be conducted. The target population consists of all the inhabitants of the Grand Nancy Metropolitan area, from which a sample is drawn from the electoral lists (households) in a random manner to ensure representativeness. In order to ultimately include 2000 people in the study
Description: Anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area
Measure: Anti-SARS-CoV-2 IgT (IgM/IgA/IgG) seropositivity Time: through study completion, an average of 4 hoursDescription: To estimate the proportion of occurrence of an episode of clinical symptoms since the beginning of the epidemic among seropositive people using self report questionnaires.
Measure: Proportion of asymptomatic, symptomatic cases among seropositive people Time: through study completion, an average of 4 hoursDescription: To estimate the proportion of asymptomatic cases (asymptomatic fraction) by the proportion of seropositive individuals who did not show any sign or symptom of COVID-19 since the beginning of the epidemic in France (mid-February).
Measure: Proportion of asymptomatic cases among seropositive people Time: through study completion, an average of 4 hoursDescription: To understand susceptibility factors to infection by comparing infected and uninfected persons on the basis of age, sex, weight status, smoking status, occupation and education.
Measure: Identification of risk groups - Anti-SARS-CoV-2 IgT seropositivity by age, sex and as a function of weight status, smoking status, work activity and social status. Time: through study completion, an average of 4 hoursDescription: Determining the prevalence of seropositive people according to the level of social disadvantage
Measure: Proportion of seropositive subjects according to the level of social disadvantage measured by the EPICES score Time: through study completion, an average of 4 hoursDescription: To estimate the prevalence of infected households
Measure: Proportion of infected households Time: through study completion, an average of 4 hoursDescription: To provide knowledge on intra-household dissemination
Measure: Anti-SARS-CoV-2 IgT seropositivity in the household Time: through study completion, an average of 4 hoursDescription: To develop symptom association profiles in seropositive subjects
Measure: Clinical expression patterns of infection by symptom/antibody association Time: through study completion, an average of 4 hoursDescription: To study the serum distribution of seropositive people, particularly in each symptom typology group.
Measure: Serological Response to Infection Time: through study completion, an average of 4 hoursDescription: To use the results of the SARS-CoV-2 seroprevalence testing campaign and questionnaires to refine our knowledge of the current and future situation and make better projections with better calibrated mathematical models of SIR infectious diseases.
Measure: Anti-SARS-CoV-2 IgT seropositivity Time: through study completion, an average of 4 hoursDescription: 10. To evaluate the in vitro neutralisation capacity of the viral infectivity of the antibodies detected.
Measure: • Evaluation of serum neutralisation of persons positive for anti-SARS-CoV-2 antibodies, of the infectivity of viral strains in cell culture: percentage neutralisation compared to a viral strain not exposed to seropositive serum. Time: through study completion, an average of 4 hoursAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports